To unravel NGFR-driven properties of MBM, we used a customized shRNA targeting the exon 3 of NGFR to perform a stable, doxycycline (DOX)-inducible knockdown (KD) in conventional melanoma cells (A375, WM35) and BMCs ~7–14 days after DOX-treatment (Fig. 7a, upper panel). The gene discussed is NGFR; the disease is melanoma.